Emerging classes of therapeutics exacerbate the challenges in drug discovery because they often force the rapid adoption of new assay techniques or require different data representations. Partnerships between biologists and medicinal chemists are driving development in novel drug modalities, including technological advances in protein degraders, peptide therapeutics, anti-body development, cell and gene therapies, and RNA-based therapeutics.